Will tarloxotinib finally break the HER2 barrier in lung cancer?
(University of Colorado Anschutz Medical Campus) By pairing a potent HER2/EGFR inhibitor with a targeting mechanism specific to tumors, researchers show that tarloxotinib is far more active against HER2 lung cancer cell lines than even the most successful existing HER2/EGFR inhibitors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 7, 2018 Category: Cancer & Oncology Source Type: news

Is a Shorter Trastuzumab Duration a Cost-Effective Option in HER2+ Breast Cancer?
Researchers compared the cost effectiveness of two durations of trastuzumab in HER2+ breast cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - November 1, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

A Closer Look at HER2-Targeted Therapies
Dr. Adam Brufsky speaks withCancer Network about the evolution and future of HER2-targeted therapy. (Source: CancerNetwork)
Source: CancerNetwork - October 31, 2018 Category: Cancer & Oncology Authors: Adam Brufsky, MD, PhD Source Type: news

First PI3K Inhibitor to Improve Outcomes in HR+/HER2 − Breast Cancer
The SOLAR-1 trial tested whether the PI3K inhibitor alpelisib improved outcomes in HR+, HER2 − breast cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - October 31, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

City of Hope opens CAR T trial for HER2 breast cancer patients with brain metastases
(City of Hope) Women with HER2-positive breast cancer that has spread to the brain need more treatment options, and City of Hope and Mustang Bio Inc. are meeting that challenge. A new City of Hope chimeric antigen receptor (CAR) T cell trial -- the first to focus on HER2-postive breast cancer patients with brain metastases -- is now enrolling potential participants. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 30, 2018 Category: International Medicine & Public Health Source Type: news

Could Low-Risk Breast Cancer Patients Benefit From Shorter Trastuzumab Treatment?
A subgroup analysis of Short-HER looked at the differences in 5-year DFS rates for 9 weeks vs 1 year of trastuzumab for HER2+ breast cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - October 26, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

PI3K Inhibitor Doubles PFS in HR+/HER2- Breast Cancer
(MedPage Today) -- Benefit limited to patients with PIK3CA mutations (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - October 22, 2018 Category: Primary Care Source Type: news

Targeting specific genomic mutation in breast cancer improves outcomes, first study shows
(European Society for Medical Oncology) Targeting a common mutation in patients with hormone receptor positive (HR+) HER2 negative (HER2-) advanced breast cancer with the alpha-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib significantly improves progression-free survival, according to late-breaking results reported at ESMO 2018. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 22, 2018 Category: Cancer & Oncology Source Type: news

A New Type of Treatment Shows Promise Against Aggressive Breast Cancer
This study is proof of principle that we should keep going,” Litton says. She is investigating whether there is a way for people who have already started chemotherapy to learn whether they will respond to the standard cycle of chemotherapy drugs, or should be switched to immunotherapy combinations for better results. Adams is also hopeful that other immunotherapy drugs may be developed that are more effective in activating the immune system against breast cancer cells specifically. “I expect these results will really invigorate the field and bring new research to help patients,” she says. (Source: TIME: Health)
Source: TIME: Health - October 20, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized breast cancer news healthytime Source Type: news

HER2+ early breast cancers where shorter-course trastuzumab could be an option
(European Society for Medical Oncology) Women with HER2-positive early breast cancer with small tumours have similar disease-free survival and lower risk of cardiac toxicity with a nine-week course of adjuvant trastuzumab compared to those treated for one year, according to a subgroup analysis of the Short-HER trial reported at ESMO 2018 Congress in Munich. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 19, 2018 Category: Cancer & Oncology Source Type: news

Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer
An otherwise healthy 58-year-old woman with a history of breast cancer presents to the clinic with newly diagnosed metastatic disease; eventual abdominal CT showed a mass in the transverse colon with ascites and peritoneal nodularity. What is the best initial systemic treatment for her? (Source: CancerNetwork)
Source: CancerNetwork - October 17, 2018 Category: Cancer & Oncology Authors: Jennifer Weiss, MD, Anosheh Afghahi, MD, Elena Shagisultanova, MD, PhD, Jennifer R. Diamond, MD Source Type: news

Dual HER2-Targeting in the Adjuvant Setting: Where We Have Been and Where We Are Going
This article discusses the advances in HER2-targeted therapy, in both the metastatic and adjuvant settings, with a focus on those with early-stage breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - October 17, 2018 Category: Cancer & Oncology Authors: Anureet C. Copeland, MD, Carey K. Anders, MD Source Type: news

FDA Approves Talzenna (talazoparib) for gBRCAm HER2-Negative Locally Advanced or Metastatic Breast Cancer
On October 16, 2018, the Food and Drug Administration approved talazoparib (Talzenna, Pfizer Inc.), a poly (ADP-ribose) polymerase (PARP) inhibitor, for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm),... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 16, 2018 Category: Drugs & Pharmacology Source Type: news

Roche ’s Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced the phase III KATHERINE study met its primary endpoint, showing Kadcyla ® (trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival, iDFS) compared to Herceptin® (trastuzumab) as an adjuvant (after surgery) treatment in people with HER2-positive early breast cancer (eBC) who have residual di sease (pathological invasive residual disease in the breast and/or axillary nodes) present following neoadjuvant (before surgery) treatment. (Source: Roche Media News)
Source: Roche Media News - October 15, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced the phase III KATHERINE study met its primary endpoint, showing Kadcyla ® (trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival, iDFS) compared to Herceptin® (trastuzumab) as an adjuvant (after surgery) treatment in people with HER2-positive early breast cancer (eBC) who have residual di sease (pathological invasive residual disease in the breast and/or axillary nodes) present following neoadjuvant (before surgery) treatment. (Source: Roche Investor Update)
Source: Roche Investor Update - October 15, 2018 Category: Pharmaceuticals Source Type: news

HER2-Targeted Cancer Vaccine Shows Promise in Early Trial
A novel cancer vaccine targeting HER2-positive malignancies has progressed quickly from mouse trials into early-phase human trials, with promising results. (Source: CancerNetwork)
Source: CancerNetwork - October 9, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)
Mutations in ERBB2, the gene encoding epidermal growth factor receptor (EGFR) family member HER2, are common in and drive the growth of "HER2-negative" (not ERBB2 amplified) tumors but are rare in "HER2-positive" (ERBB2 amplified) breast cancer. We analyzed DNA-sequencing data from HER2-positive patients and used cell lines and a patient-derived xenograft model to test the consequence of HER2 mutations on the efficacy of anti-HER2 agents such as trastuzumab, lapatinib, and neratinib, an irreversible pan-EGFR inhibitor. HER2 mutations were present in ~7% of HER2-positive tumors, all of which were metasta...
Source: Signal Transduction Knowledge Environment - October 9, 2018 Category: Science Authors: Cocco, E., Javier Carmona, F., Razavi, P., Won, H. H., Cai, Y., Rossi, V., Chan, C., Cownie, J., Soong, J., Toska, E., Shifman, S. G., Sarotto, I., Savas, P., Wick, M. J., Papadopoulos, K. P., Moriarty, A., Cutler, R. E., Avogadri-Connors, F., Lalani, A. Tags: STKE Research Articles Source Type: news

Can Trastuzumab Duration Be Shortened in HER2-Positive Breast Cancer?
The Short-HER study was unable to show noninferiority of 9 weeks of trastuzumab compared with the standard 1 year in women with HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - October 4, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

How Scientists Are Treating Breast Cancer Using the Immune System
As a pharmacist, Kathy James considers herself well educated about the importance of getting regular cancer screenings. Even though the 55-year-old had no history of cancer in her family, she never skipped her regular mammograms, and she gave herself regular breast exams. So she was dumbfounded when, during one of those self-exams in May 2017, she felt a marble-size lump in her left breast. A visit to the doctor confirmed it. “The radiologist came in with his hands in his pockets and looked down and said, ‘It doesn’t look good,'” James says. After a biopsy, James and her husband learned she had meta...
Source: TIME: Health - October 4, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized breast cancer news Frontiers of Medicine Source Type: news

How Scientists Are Treating Breast Cancer Using the Immune System
As a pharmacist, Kathy James considers herself well educated about the importance of getting regular cancer screenings. Even though the 55-year-old had no history of cancer in her family, she never skipped her regular mammograms, and she gave herself regular breast exams. So she was dumbfounded when, during one of those self-exams in May 2017, she felt a marble-size lump in her left breast. A visit to the doctor confirmed it. “The radiologist came in with his hands in his pockets and looked down and said, ‘It doesn’t look good,'” James says. After a biopsy, James and her husband learned she had meta...
Source: TIME: Science - October 4, 2018 Category: Science Authors: Alice Park Tags: Uncategorized breast cancer news Frontiers of Medicine Source Type: news

Vaccine Tx Shows Promise in HER2-Positive Cancers
(MedPage Today) -- Phase I data reveal activity in half of treated patients (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 2, 2018 Category: Hematology Source Type: news

Vaccine Shows Promise Against a Range of Cancers
Using the patients' own blood cells, researchers at the U.S. National Cancer Institute modified immune cells and created personalized vaccines to target HER2-positive cancers throughout the bod (Source: WebMD Health)
Source: WebMD Health - October 1, 2018 Category: Consumer Health News Source Type: news

Medical News Today: New cancer vaccine may tackle HER2-positive tumors
A new cancer vaccine shows promise for treating a range of more aggressive HER2-positive cancers in an early, phase I clinical trial. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 1, 2018 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

For HER2+ Breast Cancer, Anthracyclines and Trastuzumab Are Safer in Sequence For HER2+ Breast Cancer, Anthracyclines and Trastuzumab Are Safer in Sequence
Treating operable HER2-positive breast cancer with anthracyclines and trastuzumab in sequence works as well as giving them together, and it's safer, researchers suggest.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 21, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

New way to target advanced breast cancers
(Jackson Laboratory) IL1b, a member of the interleukin 1 family of cytokines (proteins released by certain cells of the immune system) drives the inflammation often found in cancer, and appears as an 'IL1 signature' in women with HER2-negative metastatic breast cancer. This signature can not only serve as a diagnostic tool for HER2-negative cancers but also offer an effective treatment target. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 20, 2018 Category: Cancer & Oncology Source Type: news

When to Monitor LV Function in Cancer Drug Therapy When to Monitor LV Function in Cancer Drug Therapy
Recent guidelines on monitoring left ventricular function in patients undergoing HER2-targeting therapy might be having unintended consequences, said one expert during a debate here.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 17, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

FDA lifts partial hold on Mersana cancer drug trial, but shares fall
Shares of Cambridge-based Mersana Therapeutics Inc. plunged Monday despite announcing that the FDA would allow it to fully restart a cancer drug trial that was paused in July after one patient died. Mersana (Nasdaq: MRSN) said Monday that regulators had lifted a partial clinical hold on an early-stage study of its lead drug, XMT-1522, which targets tumors that over-express a protein called HER2. The partial hold, which had prevented the company from enrolling new patients, was put in place af ter… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 17, 2018 Category: Biotechnology Authors: Allison DeAngelis Source Type: news

Mitochondrial Protein Offers Potentially Novel Target for HER2+ Breast Cancer
A new laboratory study has shed some light on how mitochondrial metabolism is altered in breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - September 11, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Does Sequential vs Concurrent Treatment Change Outcomes in HER2+ Breast Cancer?
Outcomes for patients with HER2-positive breast cancer did not differ when treated with sequential chemotherapy plus trastuzumab compared with a concurrent approach. (Source: CancerNetwork)
Source: CancerNetwork - September 7, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Mayo Clinic researchers identify a potential new approach to treat HER2 positive breast cancer
(Mayo Clinic) Researchers at Mayo Clinic have identified an important new pathway by which HER2 positive breast cancers grow and have discovered that a dietary supplement called cyclocreatine may block the growth of HER2 positive breast cancer. Their findings were published today in Cell Metabolism. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 30, 2018 Category: Cancer & Oncology Source Type: news

PARP Inhibitor Offers Improved Quality of Life in Advanced Breast Cancer
Treatment with talazoparib improved quality of life vs physician ’s choice of chemotherapy in patients with HER2-negative advanced breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - August 29, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Chemotherapy for HER2-Negative Metastatic Breast Cancer Chemotherapy for HER2-Negative Metastatic Breast Cancer
Choice of chemotherapy for HER2-negative metastatic breast cancer depends on tumor burden, health status, prior treatments, and patient preferences.Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 24, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation
Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint showing an improvement in progression-free survival (PFS). SOLAR-1 is evaluating BYL719 in combination with fulvestrant compared to fulvestrant alone in postmenopausal women and men with hormone-receptor positive, (Source: World Pharma News)
Source: World Pharma News - August 23, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

PARP inhibitor improves progression-free survival in patients with advanced breast cancers
(University of Texas M. D. Anderson Cancer Center) In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 15, 2018 Category: International Medicine & Public Health Source Type: news

Could HER2 Amplification Aid in the Prognosis of HER2-Positive Breast Cancer?
The presence of HER3 expression and a high HER2/CEP17 ratio distinguish a group of invasive HER2-positive ductal breast cancer patients who have a worse prognosis. (Source: CancerNetwork)
Source: CancerNetwork - August 13, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Adding TKIs Could Increase Responses in Metastatic HER2+ Breast Cancer
A laboratory study found that combining anti-HER2 TKIs with trastuzumab and pertuzumab can result in enhanced anticancer activity in HER2+ breast cancer cell lines. (Source: CancerNetwork)
Source: CancerNetwork - August 7, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Women On Herceptin Need Regular Heart Checks
Women who take the chemotherapy drug trastuzumab (Herceptin) for HER2-positive breast cancer can be at higher risk for heart failure and should have their hearts monitored during treatment, new research finds. The complication is not common, and in many cases, the benefits of the chemotherapy still outweigh the risks. But regular checks should be a priority. (Source: WebMD Health)
Source: WebMD Health - August 7, 2018 Category: Consumer Health News Source Type: news

Heart Monitoring a Must for Breast Cancer Patients on Herceptin
TUESDAY, Aug. 7, 2018 -- The widely used chemotherapy drug trastuzumab (Herceptin) can be life-saving for women with HER2-positive breast cancer, a particularly aggressive form of the disease. But new research now adds to mounting evidence that the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 7, 2018 Category: General Medicine Source Type: news

FDA Grants First Approval for CA Drug Under New Pilot Programs
Ribociclib approved in combo with AI as endocrine tx for HR - positive, HER2 - negative advanced breast CA (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 24, 2018 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Institutional, Source Type: news

FDA approves first cancer drug through new oncology review pilot that enables greater development efficiency
The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy. (Source: World Pharma News)
Source: World Pharma News - July 18, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Kisqali (ribociclib) Approved for Additional Indications in HR+/HER2- Advanced Breast Cancer
Basel, July 18, 2018 - Novartis today announced a new approval for Kisqali (ribociclib) from the US Food and Drug Administration (FDA) for women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 18, 2018 Category: Drugs & Pharmacology Source Type: news

Excelera ® Specialty Pharmacy Network Announces Access to Breast...
The U.S. Food and Drug Administration approved NERLYNX (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer in July 2017...(PRWeb July 17, 2018)Read the full story at https://www.prweb.com/releases/2018/06/prweb15575484.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 17, 2018 Category: Pharmaceuticals Source Type: news

Trastuzumab Increases PFS in Women With HER2/neu Uterine Cancer Trastuzumab Increases PFS in Women With HER2/neu Uterine Cancer
This well-done study should prompt oncologists to consider adding trastuzumab to carboplatin-paclitaxel treatment for women with advanced HER2/neu-positive uterine cancer, says Dr Maurie Markman.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 13, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Promising clinical trial results of tucatinib with T-DM1 against HER2+ breast cancer
(University of Colorado Anschutz Medical Campus) Of 57 patients treated, 48 percent responded to the combination, with cancer control of median 8.2 months. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 10, 2018 Category: Cancer & Oncology Source Type: news

ASCO Updates Guideline on Management of HER2-Positive Breast Cancer
An update to guidelines from ASCO on the optimal management of patients with HER2+ breast cancer offers recommendations on timing and sequence of therapies. (Source: CancerNetwork)
Source: CancerNetwork - July 9, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

ASCO Updates Clinical Guidelines for HER2+ Breast Cancer ASCO Updates Clinical Guidelines for HER2+ Breast Cancer
ASCO has updated its 2014 guidelines for systemic treatment of HER2+ breast cancer and also for brain metastases but did not change the recommendations.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 5, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Gene Mutations Dictate Treatment in NCI Clinical Trial
More than 40 patients with mesothelioma have been screened for NCI-MATCH, the novel clinical trial pairing tumor-related gene abnormalities with a drug targeting the corresponding mutation, regardless of cancer type. The multicenter program is the largest precision medicine clinical trial ever conducted, with more than 5,500 patients already participating nationwide. The National Cancer Institute (NCI) sponsors the phase II trial called Molecular Analysis for Therapy Choice (MATCH), which opened in 2015. The study was designed for patients with various solid tumors, myeloma and lymphoma that have progressed after standard-...
Source: Asbestos and Mesothelioma News - July 5, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Novel pretargeted radionuclide therapy for HER2-expressing cancers shows promise
(Society of Nuclear Medicine and Molecular Imaging) In a mouse model, researchers have demonstrated that a novel, affibody-based pretargeted radionuclide therapy for HER2 (human epidermal growth factor receptor 2)-expressing cancers is non-toxic to the kidneys and improves survival. The study is reported in The Journal of Nuclear Medicine's July featured article of the month. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 2, 2018 Category: Cancer & Oncology Source Type: news

TRBV Gene Use Could Act as Biomarker in HER2+ Breast Cancer
Direct measurements of TRBV genes could provide a biomarker to predict response to dual HER2 blockade in women with HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 26, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news